MA53129A - Inhibiteurs de l'histone désacétylase - Google Patents
Inhibiteurs de l'histone désacétylaseInfo
- Publication number
- MA53129A MA53129A MA053129A MA53129A MA53129A MA 53129 A MA53129 A MA 53129A MA 053129 A MA053129 A MA 053129A MA 53129 A MA53129 A MA 53129A MA 53129 A MA53129 A MA 53129A
- Authority
- MA
- Morocco
- Prior art keywords
- histone deacetylase
- deacetylase inhibitors
- inhibitors
- histone
- deacetylase
- Prior art date
Links
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697498P | 2018-07-13 | 2018-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53129A true MA53129A (fr) | 2021-05-19 |
Family
ID=67480370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053129A MA53129A (fr) | 2018-07-13 | 2019-07-12 | Inhibiteurs de l'histone désacétylase |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210276978A1 (fr) |
| EP (1) | EP3820859B1 (fr) |
| JP (2) | JP7414820B2 (fr) |
| KR (1) | KR20210031704A (fr) |
| CN (1) | CN112424184A (fr) |
| AR (1) | AR115768A1 (fr) |
| AU (1) | AU2019300036A1 (fr) |
| CA (1) | CA3106355A1 (fr) |
| EA (1) | EA202190077A1 (fr) |
| IL (2) | IL279940B2 (fr) |
| MA (1) | MA53129A (fr) |
| MX (1) | MX2021000468A (fr) |
| SG (1) | SG11202012916WA (fr) |
| TW (1) | TWI809146B (fr) |
| WO (1) | WO2020014605A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| CA3049443A1 (fr) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Inhibiteurs bicycliques d'histone desacetylase |
| JP7152471B2 (ja) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス，インコーポレーテッド | ヒストン脱アセチル化酵素の二環阻害剤 |
| TW202332437A (zh) | 2021-12-03 | 2023-08-16 | 美商譚格醫療公司 | 新穎ｈｄａｃ抑制劑及其治療用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461189B2 (en) * | 2007-06-27 | 2013-06-11 | Merck Sharp & Dohme Corp. | Pyridyl derivatives as histone deacetylase inhibitors |
| EP2712655B1 (fr) * | 2011-04-28 | 2019-12-18 | The Broad Institute, Inc. | Inhibiteurs de l'histone désacétylase |
| WO2016018795A1 (fr) * | 2014-07-28 | 2016-02-04 | The General Hospital Corporation | Inhibiteurs d'histone désacétylase |
| PT3319959T (pt) * | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| AU2017363268A1 (en) * | 2016-11-23 | 2019-05-30 | Regenacy Pharmaceuticals, Llc | Piperazine derivatives as selective HDAC1,2 inhibitors |
-
2019
- 2019-07-12 US US17/260,193 patent/US20210276978A1/en not_active Abandoned
- 2019-07-12 SG SG11202012916WA patent/SG11202012916WA/en unknown
- 2019-07-12 MA MA053129A patent/MA53129A/fr unknown
- 2019-07-12 IL IL279940A patent/IL279940B2/en unknown
- 2019-07-12 KR KR1020217002884A patent/KR20210031704A/ko not_active Withdrawn
- 2019-07-12 JP JP2021523578A patent/JP7414820B2/ja active Active
- 2019-07-12 CN CN201980046820.5A patent/CN112424184A/zh active Pending
- 2019-07-12 AU AU2019300036A patent/AU2019300036A1/en not_active Abandoned
- 2019-07-12 EA EA202190077A patent/EA202190077A1/ru unknown
- 2019-07-12 AR ARP190101972A patent/AR115768A1/es not_active Application Discontinuation
- 2019-07-12 CA CA3106355A patent/CA3106355A1/fr active Pending
- 2019-07-12 EP EP19746301.1A patent/EP3820859B1/fr active Active
- 2019-07-12 WO PCT/US2019/041592 patent/WO2020014605A1/fr not_active Ceased
- 2019-07-12 MX MX2021000468A patent/MX2021000468A/es unknown
- 2019-07-12 IL IL309951A patent/IL309951A/en unknown
- 2019-07-12 TW TW108124686A patent/TWI809146B/zh not_active IP Right Cessation
-
2023
- 2023-12-28 JP JP2023222406A patent/JP2024038202A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN112424184A (zh) | 2021-02-26 |
| AU2019300036A1 (en) | 2021-01-14 |
| IL309951A (en) | 2024-03-01 |
| EP3820859B1 (fr) | 2024-03-20 |
| EP3820859C0 (fr) | 2024-03-20 |
| IL279940B2 (en) | 2024-06-01 |
| CA3106355A1 (fr) | 2020-01-16 |
| IL279940B1 (en) | 2024-02-01 |
| EA202190077A1 (ru) | 2021-08-30 |
| US20210276978A1 (en) | 2021-09-09 |
| KR20210031704A (ko) | 2021-03-22 |
| WO2020014605A1 (fr) | 2020-01-16 |
| JP2021531336A (ja) | 2021-11-18 |
| IL279940A (en) | 2021-03-01 |
| EP3820859A1 (fr) | 2021-05-19 |
| MX2021000468A (es) | 2021-06-23 |
| TW202019903A (zh) | 2020-06-01 |
| AR115768A1 (es) | 2021-02-24 |
| JP2024038202A (ja) | 2024-03-19 |
| SG11202012916WA (en) | 2021-01-28 |
| TWI809146B (zh) | 2023-07-21 |
| JP7414820B2 (ja) | 2024-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3906026A4 (fr) | Inhibiteurs irréversibles de l'interaction ménine-mll | |
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP3843714A4 (fr) | Inhibiteurs de cd73 | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| IL304348A (en) | Cd73 inhibitors | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| MA52635A (fr) | Inhibiteurs de magl | |
| EP3484478A4 (fr) | Inhibiteurs d'histone désacétylase destinés à être utilisés en immunothérapie | |
| MA47305A (fr) | Inhibiteurs bicycliques d'histone désacétylase | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| MA53128A (fr) | Inhibiteurs bicycliques de l'histone désacétylase | |
| EP3624804A4 (fr) | Inhibiteurs des histone désacétylases (hdac) | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA51226A (fr) | Inhibiteurs d'histone acétyltransférase de la famille des myst | |
| EP3980011A4 (fr) | Inhibiteurs de sarm1 | |
| GB201803361D0 (en) | Histone deacetylase inhibitors | |
| IL267465A (en) | Histone deacetylase inhibitors | |
| EP3458444A4 (fr) | Inhibiteurs de l'histone désacétylase 6 et leurs utilisations |